Xiangwei Zeng, Lujian Jiang, Huili Li, Jiamou Wang, Xuan He
{"title":"MC1R通过激活Notch信号参与结直肠癌铁下垂抵抗和肿瘤侵袭。","authors":"Xiangwei Zeng, Lujian Jiang, Huili Li, Jiamou Wang, Xuan He","doi":"10.1038/s41417-025-00942-4","DOIUrl":null,"url":null,"abstract":"<p><p>Ferroptosis, a form of iron-dependent cell death, is emerging as a potential therapeutic target due to its ability to inhibit tumor growth and enhance immune responses. However, the mechanisms regulating ferroptosis and tumor metastasis, particularly in colorectal cancer (CRC), remain poorly understood. In this study, bioinformatics analysis identified MC1R as a key regulator of ferroptosis-related genes. In vitro experiments showed MC1R overexpression in CRC cell lines promotes cell proliferation and migration while inhibiting ferroptosis via downregulating ACSL4 expression, with opposite effects seen in MC1R knockdown. In vivo experiments also found MC1R-knockdown CRC cells resulted in xenograft tumors with lower volume and weight. Mechanistically, MC1R activates the Notch signaling pathway, leading to ACSL4 inhibition, which inhibits ferroptosis and, in turn, cell growth and migration. High MC1R expression in CRC correlates with poor prognosis and is negatively associated with ferroptosis levels. Targeting MC1R could offer a novel strategy to enhance ferroptosis in CRC, potentially improving patient outcomes. This study elucidates the complex interactions between MC1R, Notch signaling, and ferroptosis, providing insights for developing targeted therapies in CRC.</p>","PeriodicalId":9577,"journal":{"name":"Cancer gene therapy","volume":" ","pages":""},"PeriodicalIF":5.0000,"publicationDate":"2025-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"MC1R contributes to ferroptosis resistance and tumor aggressiveness in colorectal cancer by activating Notch signaling.\",\"authors\":\"Xiangwei Zeng, Lujian Jiang, Huili Li, Jiamou Wang, Xuan He\",\"doi\":\"10.1038/s41417-025-00942-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Ferroptosis, a form of iron-dependent cell death, is emerging as a potential therapeutic target due to its ability to inhibit tumor growth and enhance immune responses. However, the mechanisms regulating ferroptosis and tumor metastasis, particularly in colorectal cancer (CRC), remain poorly understood. In this study, bioinformatics analysis identified MC1R as a key regulator of ferroptosis-related genes. In vitro experiments showed MC1R overexpression in CRC cell lines promotes cell proliferation and migration while inhibiting ferroptosis via downregulating ACSL4 expression, with opposite effects seen in MC1R knockdown. In vivo experiments also found MC1R-knockdown CRC cells resulted in xenograft tumors with lower volume and weight. Mechanistically, MC1R activates the Notch signaling pathway, leading to ACSL4 inhibition, which inhibits ferroptosis and, in turn, cell growth and migration. High MC1R expression in CRC correlates with poor prognosis and is negatively associated with ferroptosis levels. Targeting MC1R could offer a novel strategy to enhance ferroptosis in CRC, potentially improving patient outcomes. This study elucidates the complex interactions between MC1R, Notch signaling, and ferroptosis, providing insights for developing targeted therapies in CRC.</p>\",\"PeriodicalId\":9577,\"journal\":{\"name\":\"Cancer gene therapy\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.0000,\"publicationDate\":\"2025-10-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer gene therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41417-025-00942-4\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer gene therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41417-025-00942-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
MC1R contributes to ferroptosis resistance and tumor aggressiveness in colorectal cancer by activating Notch signaling.
Ferroptosis, a form of iron-dependent cell death, is emerging as a potential therapeutic target due to its ability to inhibit tumor growth and enhance immune responses. However, the mechanisms regulating ferroptosis and tumor metastasis, particularly in colorectal cancer (CRC), remain poorly understood. In this study, bioinformatics analysis identified MC1R as a key regulator of ferroptosis-related genes. In vitro experiments showed MC1R overexpression in CRC cell lines promotes cell proliferation and migration while inhibiting ferroptosis via downregulating ACSL4 expression, with opposite effects seen in MC1R knockdown. In vivo experiments also found MC1R-knockdown CRC cells resulted in xenograft tumors with lower volume and weight. Mechanistically, MC1R activates the Notch signaling pathway, leading to ACSL4 inhibition, which inhibits ferroptosis and, in turn, cell growth and migration. High MC1R expression in CRC correlates with poor prognosis and is negatively associated with ferroptosis levels. Targeting MC1R could offer a novel strategy to enhance ferroptosis in CRC, potentially improving patient outcomes. This study elucidates the complex interactions between MC1R, Notch signaling, and ferroptosis, providing insights for developing targeted therapies in CRC.
期刊介绍:
Cancer Gene Therapy is the essential gene and cellular therapy resource for cancer researchers and clinicians, keeping readers up to date with the latest developments in gene and cellular therapies for cancer. The journal publishes original laboratory and clinical research papers, case reports and review articles. Publication topics include RNAi approaches, drug resistance, hematopoietic progenitor cell gene transfer, cancer stem cells, cellular therapies, homologous recombination, ribozyme technology, antisense technology, tumor immunotherapy and tumor suppressors, translational research, cancer therapy, gene delivery systems (viral and non-viral), anti-gene therapy (antisense, siRNA & ribozymes), apoptosis; mechanisms and therapies, vaccine development, immunology and immunotherapy, DNA synthesis and repair.
Cancer Gene Therapy publishes the results of laboratory investigations, preclinical studies, and clinical trials in the field of gene transfer/gene therapy and cellular therapies as applied to cancer research. Types of articles published include original research articles; case reports; brief communications; review articles in the main fields of drug resistance/sensitivity, gene therapy, cellular therapy, tumor suppressor and anti-oncogene therapy, cytokine/tumor immunotherapy, etc.; industry perspectives; and letters to the editor.